The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), are dysregulated in a wide variety of human cancers and are linked with tumorigenesis and metastatic progression. Vascular endothelial growth factor (VEGF) also plays a key role in tumor angiogenesis and progression by stimulating the proangiogenic signaling of endothelial cells via activation of VEGF receptor tyrosine kinases (VEGFRs).
Introduction
are mostly located in endothelial cells (reviewed in ref. 10) . VEGFR activation occurs through VEGF binding, which triggers receptor dimerization, tyrosine kinase activation, and phosphorylation of tyrosine residues. Of the two VEGFRs, VEGFR-2 is believed to be a major driver of tumor angiogenesis, which plays important roles in tumor malignancy (such as sustaining tumor growth) and in blood-borne metastasis (11) .
VEGF expression is upregulated by changes associated with cancer, including hypoxia, proto-oncogene activation, loss of tumor suppressor gene expression, and growth factor stimuli in tumors (12, 13) . Its overexpression has been reported to correlate with the degree of vascularity, aggressive disease, and poor prognosis in the majority of human solid tumors (14) (15) (16) (17) , making the VEGF/VEGFR axis an attractive molecular target for cancer therapy. Indeed, the monoclonal anti-VEGF antibody bevacizumab (18) and several RTK inhibitors targeting VEGFRs, such as sunitinib (19), sorafenib (20), and pazopanib (21), have proven to be efficacious in clinical settings.
The above-mentioned findings highlight the possibility that simultaneous inhibition of c-Met and VEGFRs by a small-molecule inhibitor may result in broader and more potent antitumor efficacy. Here, we report the characterization of T-1840383, a novel ATP-competitive multitargeted kinase inhibitor that preferentially inhibits c-Met and 488-conjugated anti-mouse IgG polyclonal antibody (Invitrogen). Tube formation by endothelial cells was visualized using fluorescence imaging (Discovery-1 system, Molecular Devices) according to the manufacturer's protocol, "Angiogenesis Tube Formation." The filament length and number of branch points were quantified by using Metamorph® software (Molecular Devices).
VEGFR-2, in various functional cellular assays and the evaluation of its in vivo

Materials and Methods
T-1840383
N-[4-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-a]pyridin-6-yl}oxy)-3-fluoroph
Cell scattering assay and E-cadherin expression analysis
A549 cells were seeded onto poly-lysine-coated glass-bottom dishes (2,000 cells/dish) and were allowed to form colonies of appropriate size for 5 days. Controls or T-1840383 were added to each dish. After a 1-h incubation, 50 ng/mL HGF (R&D Systems) was added to the dishes. Cell scattering was stimulated for 48 h under a mild hypoxic condition (3% O 2 ). Cells were stained using a Diff-Quik stain kit (Sysmex). For E-cadherin expression analysis, scattering-stimulated cells were fixed with 4% paraformaldehyde and were subjected to immunofluorescence staining using anti-E-cadherin primary antibody and Alexa Fluor 488-conjugated anti-rabbit IgG antibody. Nucleic acid was stained with propidium iodide. Cell invasion was assessed using Matrigel Invasion Chambers (BD Biosciences).
Matrigel invasion assay
A549 cells or SUIT-2 cells were placed in the upper chamber, and T-1840383 was added to both the upper and lower chambers. Cell invasion was then initiated by adding HGF to the bottom chamber (50 ng/mL). After 72 h, noninvading cells were removed with cotton swabs. Cells that invaded through the Matrigel were stained using a Diff-Quik stain kit, and the number of invading cells was quantified using WinROOF software (Mitani Corp.).
Cell proliferation assay
Cancer cells and HUVECs were seeded in 96-well plates in appropriate media with 10% fetal bovine serum (FBS) and human endothelial serum-free medium (Invitrogen), respectively. The following day, serial dilutions of T-1840383 or 0.1% DMSO were added to each well. Cancer cells were then incubated for a further 72 h. Proliferation of HUVECs was stimulated with 60 ng/mL recombinant human VEGF for 120 h. After incubation, cell proliferation was determined using a Cell Counting Kit-8 (DOJINDO Laboratories). IC 50 values were calculated by nonlinear regression analysis using GraphPad Prism (GraphPad Software, Inc.). 
Western blotting
Antibodies were purchased from Cell Signaling Technology. For analysis of A549 cells and HUVECs, c-Met and VEGFR2 phosphorylation were stimulated with 50 ng/mL HGF for 10 min and 100 ng/mL VEGF for 5 min, respectively. All cells were lysed in RIPA buffer (Pierce) with protease and phosphatase inhibitors. In the case of the tumor samples, tissues were homogenized in RIPA buffer with protease and phosphatase inhibitors. Samples were then subjected to western blot analysis. Detection was performed using enhanced chemiluminescence reagent (GE Healthcare).
Tumor xenograft models
All animal experiments were conducted according to the guidelines of the Takeda Experimental Animal Care and Use Committee. Athymic nude mice (BALB/cA Jcl-nu/nu) were purchased from Japan CLEA. For tumor models, cancer cells in Hanks' balanced salt solution (HBSS; Gibco, Invitrogen Corp.) were subcutaneously (s.c.) inoculated into the hind flank of 6-to 7-week-old mice (day 0). For the study with Mice were euthanized when they became moribund. Statistical analysis was performed by a Log-rank test using GraphPad Prism.
for CD31 was performed using rabbit anti-CD31 polyclonal antibody (Spring 
T-1840383 inhibits HGF-induced c-Met phosphorylation and HGF-dependent cellular phenotypes
In cell-based assays using A549 cells, T-1840383 inhibited HGF-stimulated c-Met phosphorylation with an IC 50 value of 8.8 nmol/L (Fig. 1B) . It also inhibited A549 cell scattering stimulated with HGF (Fig. 1C) trigger destabilization of adherens junctions by downregulation of E-cadherin (23), expression level of E-cadherin was examined in a similar cell-scattering assay. As expected, HGF-stimulated cell scattering was accompanied by diminished expression of E-cadherin on cell membrane, which was inhibited by T-1840383 in a concentration-dependent manner (Fig. 1D) . T-1840383 also displayed similar potency against HGF-induced A549 cell invasion in a Matrigel invasion assay ( Fig. 1E and Supplementary Fig. S2 ).
T-1840383 inhibits c-Met-dependent cell proliferation in vitro
The effects of T-1840383 on cell proliferation were evaluated using a panel of cancer 
T-1840383 inhibits VEGF receptor-2 phosphorylation and VEGF signaling in
HUVECs
Because T-1840383 also potently inhibits VEGF receptor tyrosine kinases, the effects on VEGF signaling were tested in endothelial cells. As shown in Fig Fig. 3D and 3E ). The T/C values for EBC-1 tumors were 85% and 26% at 0.5 and 1.5 mg/kg, respectively, and the tumors regressed by 22% and 52% at 5 mg/kg and 15 mg/kg, respectively. The T/C values for U-87 MG tumors were 72%, 32%, and 10% at 0.5, 1.5, and 5 mg/kg, respectively, and the tumors were almost static at 15 mg/kg. In the c-Met-independent COLO 205 tumor model, T-1840383 showed slightly less potent but still substantial antitumor activity than it did in the c-Met-dependent tumor models, where the T/C values were 30% and 13% at 5 mg/kg and 15 mg/kg, respectively ( 
T-1840383 inhibits tumor angiogenesis
To further understand the mechanism of tumor growth inhibition by T-1840383, 4A and 4B). In similar dose-dependent manners, T-1840383 treatment also led to a decreased tendency of cell mitosis (Ki67) and a significant increase in apoptosis (TUNEL) in the A549 tumor xenografts (Fig. 4C and 4D) . Together, these results suggest that targeting tumor angiogenesis is one of the mechanisms by which T-1840383 inhibits growth of c-Met-independent tumors in vivo.
Antitumor activities of T-1840383 in a gastric tumor peritoneal dissemination model
To extend the finding that T-1840383 potently inhibits the growth c-Met-dependent cancer cells, T-1840383 was further evaluated in a mouse model of peritoneal dissemination using c-Met-dependent gastric cancer NUGC-4-luc cells. In this model, tumor growth was monitored noninvasively with bioluminescence emitted from NUGC-4-luc cells in mice. As shown in Fig. 5A and 5B, vehicle-treated mice showed a significant increase in tumor burden over the monitoring time from day 14 to day 41 
vehicle-treated mice, on the basis of in vivo imaging analysis, one mouse apparently became tumor-free and showed an exceptionally longer survival than the others, probably due to rejection of the tumor challenge.
c-Met expression and activation under hypoxia
Hypoxia, which is known to be a major stimulator of VEGF and consequent angiogenesis, has been shown to promote invasive tumor growth by transcriptional activation of c-met and by sensitizing cells to HGF stimulation (27). To explore this finding in our systems, we investigated c-Met expression and HGF-induced cell invasion in response to hypoxia. Hypoxia upregulated c-Met expression compared to normoxia (Fig. 6A) . Moreover, we found that hypoxia-induced c-Met phosphorylation in A549 cancer cells without HGF stimulation while serum starvation had no such effects on c-Met expression and activation. Similar effects were seen in Caki-1 renal cell carcinoma, SUIT-2 pancreatic cancer, and U-87 MG glioma cells (Fig. 6B ). In addition, hypoxia augmented SUIT-2 cell invasion induced by HGF compared to normoxia (Fig. 6C) , suggesting functional relevance for the c-Met pathway in cancer cell invasive growth under hypoxia. We believe that inhibition of angiogenesis represents a mechanism by which T-1840383 manifests a wide spectrum of its antitumor activities. Indeed, compared to the selective inhibitors of VEGFR or c-Met, T-1840383 showed a broad in vivo antitumor spectrum (Supplementary Table S2 ).
Several small-molecule inhibitors, including cabozantinib/XL184 (37) and foretinib/XL880 (38) , that simultaneously target c-Met and VEGFRs have been 
